Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAGIO-3 open-label extension of KarXT + KarX-EC for agitation associated with Alzheimer's disease
2024-519994-20-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 3, open-label, single-arm trial of xanomeline and KarX-EC in Alzheimer's disease (AD), sponsored by Bristol Myers Squibb. Primary endpoint: Incidence of treatment-emergent adverse events. Planned start Jun 2026; status: authorised.
02
Drugs
xanomelineKarX-EC
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2024-519994-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519994-20-00.